Seoul National University Bundang Hospital (SNUBH) said Wednesday that it signed an industry-university joint technology development contract with Cube Bio to develop cancer diagnosis technology using urine.

Under the accord, SNUBH will proceed with urine-based cancer diagnosis technology and clinical trials, apply for approvals and patents in Korea and overseas, publish and present science citation index (SCI)-level papers, and develop a method to apply the technology.

The hospital plans to upgrade its cancer diagnosis technology using urine through joint clinical trials with Cube Bio. It expects to contribute significantly to the global dissemination of the technology by presenting a standard for a simple new cancer diagnosis method with no side effects.

“We hope the results of this industry-university joint technology development to serve as a foundation for K-Diagnosis’ advance into the world,” SNUBH President and CEO Paik Nam-jong said. “In the future, we will combine the know-how of both sides in various research topics to create synergy.”